Ventavis (iloprost)
- Region
- 🇪🇺 EU
- Active substance
- iloprost
- Company
- Bayer AG
- Status
- Authorised
- Therapeutic area
- Hypertension, Pulmonary
- CHMP opinion
- Thu 22 May 2003
- EU approval
- Mon 15 Sep 2003
- Application
- EMEA/H/C/000474
- ATC
- B01AC11
- Official record
- www.ema.europa.eu
Indication
Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.
Regulatory milestones
No milestones recorded in the last year.
Follow Ventavis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.